News

San Diego, CA, USA, and Munich, Germany – October 21, 2025 – selectION, Inc. (“selectION” or the “Company”), a clinical-stage biopharmaceutical company developing novel treatments for T cell-mediated autoimmune diseases, today announced the successful completion of its phase 1b proof-of-concept trial evaluating si-544, a first-in-class Kv1.3 blocker in patients diagnosed with psoriasis vulgaris.

New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity Recruitment…

si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed 75% of patients receiving si-544 experienced objective clinical improvement, of which 44% achieved clear…

By Cormac Sheridan, Staff Writer – Published by BioWorld™ – The coming months represent a crucial phase in the development of Selection Inc., a U.S.-German firm that is tackling a…

Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity Dosing of MAD stage has been initiated; first results expected for late…

Phase 1b trial is designed to evaluate safety, tolerability, and efficacy of potent Kv1.3 blocker in T-cell mediated autoimmunity – San Diego, CA, USA, and Munich, Germany – September 12,…

Novel ion channel blocker designed to combine high efficacy and durable response while maintaining full immune system functionality – San Diego, CA, USA, and Munich, Germany – May 09, 2022…

si-544, a Kv1.3 blocker with class leading selectivity and excellent preclinical safety profile, scheduled to advance towards clinical development in early 2021 SAN DIEGO, September 16, 2020 – selectION, Inc.…

SAN DIEGO, May 31, 2019 – selectION, Inc., a biotherapeutic company focused on the development of peptide ion channel blockers with class leading selectivity, announced today it has received a…